Triathlon Medical Ventures

Triathlon Medical Ventures is a venture capital firm based in Cincinnati, Ohio, founded in 2004. The firm specializes in investing in life sciences, medical devices, biotechnology, and diagnostic companies, primarily focusing on early-stage firms in the Midwest but also considering mid- to later-stage opportunities nationwide. As a registered Small Business Investment Company (SBIC), Triathlon Medical Ventures seeks to invest in companies with proprietary biomedical technology platforms or products that address significant healthcare needs. The firm typically invests between $0.5 million and $10 million and prefers to take a lead role in its investments, often requiring a seat on the board of directors for early-stage companies or serving as a board observer for later-stage investments. Triathlon Medical Ventures does not engage in investments in healthcare information technology and services.

Carrie Bates

Managing Partner and Owner

Dennis B. Costello

Co-Founder and Managing Partner

Suzette Dutch

Managing Partner and Owner

35 past transactions

Aerpio Pharmaceuticals

Venture Round in 2017
Aerpio Pharmaceuticals, a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, is dedicated to developing innovative compounds for treating ocular diseases and diabetic complications. Its lead product candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema through intravitreal injection. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 as a spin-out from Akebia Therapeutics, Aerpio adopts an outsourced approach to pharmaceutical development, leveraging the expertise of its management team.

CoLucid Pharmaceuticals

Series C in 2015
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Aerpio Pharmaceuticals

Series C in 2014
Aerpio Pharmaceuticals, a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, is dedicated to developing innovative compounds for treating ocular diseases and diabetic complications. Its lead product candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema through intravitreal injection. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 as a spin-out from Akebia Therapeutics, Aerpio adopts an outsourced approach to pharmaceutical development, leveraging the expertise of its management team.

Alluxa

Venture Round in 2014
Alluxa, Inc. specializes in the design and manufacture of precision optical thin film interference filters, catering to industries such as telecommunications, biomedical instruments, and laser systems. Established in 2007 and located in Santa Rosa, California, the company focuses on providing customized coating solutions through advanced automation and proprietary technology. Alluxa employs a patented plasma thin film deposition process, which enables it to meet high-performance requirements while maintaining cost-effectiveness for its clients. Formerly known as Sirrus Technology, Inc., Alluxa operates as a subsidiary of Vision Investment LLC.

Aerpio Pharmaceuticals

Series A in 2013
Aerpio Pharmaceuticals, a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, is dedicated to developing innovative compounds for treating ocular diseases and diabetic complications. Its lead product candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema through intravitreal injection. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 as a spin-out from Akebia Therapeutics, Aerpio adopts an outsourced approach to pharmaceutical development, leveraging the expertise of its management team.

Akebia Therapeutics

Series C in 2013
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Tolera Therapeutics

Series B in 2012
Tolera Therapeutics Inc. is a biotechnology company that specializes in developing immune modulation therapies aimed at improving organ and tissue transplantation outcomes. Founded by Dr. Maria Siemionow, the company emerged from research conducted at the Cleveland Clinic, where Dr. Siemionow has been a leading figure in microsurgery and transplantation. Tolera Therapeutics focuses on creating safer, more targeted therapies that promote long-term acceptance of transplants while minimizing the reliance on chronic immunosuppression, which often carries significant health risks. The company's innovative approach targets the human alpha-beta T-cell receptor, effectively rendering harmful T-cells inactive and enhancing the regulatory T-cell population through a unique, non-depleting signaling pathway. This research addresses critical unmet medical needs for patients with autoimmune and immune-mediated diseases, aiming to improve their quality of life.

Juventas Therapeutics

Series B in 2012
Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.

Mitralign

Series D in 2012
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

CoLucid Pharmaceuticals

Venture Round in 2011
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Akebia Therapeutics

Series B in 2011
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Celleration

Series E in 2011
Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

Tolera Therapeutics

Series B in 2010
Tolera Therapeutics Inc. is a biotechnology company that specializes in developing immune modulation therapies aimed at improving organ and tissue transplantation outcomes. Founded by Dr. Maria Siemionow, the company emerged from research conducted at the Cleveland Clinic, where Dr. Siemionow has been a leading figure in microsurgery and transplantation. Tolera Therapeutics focuses on creating safer, more targeted therapies that promote long-term acceptance of transplants while minimizing the reliance on chronic immunosuppression, which often carries significant health risks. The company's innovative approach targets the human alpha-beta T-cell receptor, effectively rendering harmful T-cells inactive and enhancing the regulatory T-cell population through a unique, non-depleting signaling pathway. This research addresses critical unmet medical needs for patients with autoimmune and immune-mediated diseases, aiming to improve their quality of life.

Endocyte

Series C in 2010
Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Akebia Therapeutics

Series A in 2009
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

BioVex Group

Venture Round in 2009
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Juventas Therapeutics

Series A in 2008
Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.

Celleration

Series D in 2008
Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

CoLucid Pharmaceuticals

Series B in 2008
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Tolera Therapeutics

Series A in 2008
Tolera Therapeutics Inc. is a biotechnology company that specializes in developing immune modulation therapies aimed at improving organ and tissue transplantation outcomes. Founded by Dr. Maria Siemionow, the company emerged from research conducted at the Cleveland Clinic, where Dr. Siemionow has been a leading figure in microsurgery and transplantation. Tolera Therapeutics focuses on creating safer, more targeted therapies that promote long-term acceptance of transplants while minimizing the reliance on chronic immunosuppression, which often carries significant health risks. The company's innovative approach targets the human alpha-beta T-cell receptor, effectively rendering harmful T-cells inactive and enhancing the regulatory T-cell population through a unique, non-depleting signaling pathway. This research addresses critical unmet medical needs for patients with autoimmune and immune-mediated diseases, aiming to improve their quality of life.

CS-Keys

Series A in 2008
CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.

HydroCision

Series H in 2008
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.

Mitralign

Series C in 2007
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

BioVex Group

Series E in 2007
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Alluxa

Venture Round in 2007
Alluxa, Inc. specializes in the design and manufacture of precision optical thin film interference filters, catering to industries such as telecommunications, biomedical instruments, and laser systems. Established in 2007 and located in Santa Rosa, California, the company focuses on providing customized coating solutions through advanced automation and proprietary technology. Alluxa employs a patented plasma thin film deposition process, which enables it to meet high-performance requirements while maintaining cost-effectiveness for its clients. Formerly known as Sirrus Technology, Inc., Alluxa operates as a subsidiary of Vision Investment LLC.

Endocyte

Series C in 2007
Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

HydroCision

Series G in 2007
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.

HydroCision

Venture Round in 2006
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.

Endocyte

Venture Round in 2006
Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Mitralign

Series B in 2006
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

Mitralign

Series B in 2006
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

CoLucid Pharmaceuticals

Series A in 2006
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Kereos

Series B in 2005
Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.

Renal Solutions

Series B in 2005
Renal Solutions is a company based in Warrendale, Pennsylvania, that specializes in the development of dialysis products and services. Founded in 2000 and acquired by Fresenius Medical Care in 2007, the company focuses on creating integrated medical devices for sorbent hemodialysis treatment. These devices provide a clinical care model tailored for patients with chronic and acute kidney failure, allowing healthcare practitioners to offer flexible and convenient treatment options. Renal Solutions aims to enhance renal care through innovative sorbent-based dialysis technologies.

Remon Medical Technologies

Series C in 2005
Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.